Join us in San Francisco for the 2nd Annual Drug Repositioning Conference, where presenters and panelists will share with the audience best practices, new technologies, case studies, and regulatory developments in drug repositioning and indications discovery.

About Drug Repositioning & Indications Discovery
Pharmaceutical companies on average spent $1.1 billion to develop and launch a new drug during the late 1990s. By 2009 the required investment had more than doubled to $2.2 billion, and the return on invested capital for new-drug development had dropped from 9% in 1995-2000 to 4% in 2009. As a result, companies have turned to drug repositioning; identifying novel indications for clinical candidates that have been discontinued for their primary indications for reasons other than safety in order to refurbish their pipelines at lower costs and to drive and sustain future profits.

Drug repositioning lowers the cost of drug discovery, as preclinical and early stage clinical trials have already been completed. This leads to a larger return on investment for new drugs. Not only have companies been able to use drugs that have not made it through clinical trials; they are also finding new ways to use drugs that already on the market. Companies have found new indications for currently marketed drugs and use in combination therapy as well. Life cycle management is also becoming more important to combat generic copies and increase ROI.

At the conference, we will highlight the following topics